Regulatory Ready Portfolio Epigenomics offers a regulatory-validated product suite with FDA-approved Epi proColon for colorectal cancer screening and CE-marked IVDs in Europe, providing a strong entry point for hospital systems, labs, and screening programs. The breadth of tests including HCCBloodTest and Epi proLung supports multi-cancer screening partnerships and cross-sell opportunities across regions. This ready-to-market portfolio is complemented by a large patent estate that can be licensed through collaborations with diagnostics manufacturers and CROs.

Intellectual Property Monetization With more than 60 granted patents on DNA methylation technologies and biomarkers, Epigenomics presents multiple IP-led monetization paths, including licensing, biomarker services, IVD development collaborations, and strategic licensing deals with diagnostic companies and contract labs. Partners can leverage the IP to accelerate new test development or integrate methylation markers into existing panels. This creates recurring revenue streams via collaboration agreements and milestone payments.

Strategic Ownership Shift Recent leadership changes and the acquisition by New Day Diagnostics signal a strategic pivot and new go-to-market approach. Opportunities exist to align with the acquirer’s distribution channels and leverage shared sales resources to accelerate market penetration. Engaging with the current executive team and transition plans can unlock co-selling and integration projects across oncology screening programs.

Market Demand Signal The company’s colorectal cancer screening leadership with an FDA-approved test, plus CE-marked blood tests for liver and lung cancers, positions it to address growing demand for non-invasive, population-wide screening. Target opportunities include hospital systems, payer programs, and national screening initiatives seeking validated blood-based assays. Partnerships around companion diagnostics and real-world evidence could drive adoption.

Expansion Partnerships Europe and North America are primary expansion targets given CE marks and FDA alignment; Potential to partner with regional distributors, large labs, and academic medical centers to scale adoption. The Next-Gen screening approach that combines protein biomarkers with DNA methylation markers offers an upsell pathway to labs seeking differentiated panels. Collaboration options include co-development, contract research, and test licensing to accelerate rollout.